Pulsus plans to buy two firms

To set up new centres in Chennai and Gurugram this year

By Author   |   Published: 3rd Jan 2018   12:01 am Updated: 2nd Jan 2018   10:17 pm
Pulsus
The company will carry out economic research and market analysis in the pharmaceuticals and medical devices space focusing on specific segments and geographies.

Hyderabad: Medical informatics company Pulsus Group associated with Hyderabad-based Omics International, is planning to expand its operations in India. Pulsus is actively pursuing acquisitions at this stage. The company is in discussion with one market analysis company in Hyderabad and another overseas company for acquisition. It plans to conclude the acquisitions in next six months.

Hyderabad-based entrepreneur Dr Srinubabu Gedela recently acquired Pulsus, which was a Canada-based medical informatics company, whose headquarters has been now moved to Singapore.

“We are looking at acquisitions where there is a best fitment. We could be investing about $60 million for acquiring these two companies, about $50 million for the overseas and $10 million for the Hyderabad-based company. Worldwide companies are aggressively looking for acquisitions and we too believe acquisitions will help us expand faster,” Dr Srinubabu Gedela, CEO, Pulsus Group told Telangana Today.

Pulsus focuses on pharmacovigilance (drug safety) activity covering archival and monitoring of individual case studies. The company has collaborations with 50 scientific societies and pharmaceutical companies.

The company will carry out economic research and market analysis in the pharmaceuticals and medical devices space focusing on specific segments and geographies. It plans to get into regulatory documentation space in near future. Pulsus has been carrying out adverse reporting documentation for pharmaceutical companies in the US and Canada.

Gedela, said, “Significant research worldwide is happening in the oncology segment. Majority of funding from WHO and NIH is going into this segment. Prostrate, breast, colon, pancreatic and skin cancer are gaining prominence as both pharmaceutical companies and research agencies are looking at improved solutions to these types of cancers.”

Pulsus is planning to expand its operations in India with two new centres-Chennai and Gurugram. Operations in Chennai will begin this month followed by Gurugram in February. The company’s headcount will go up from the current 1,000 to 2,000 this year. A majority of these personnel are operating from Hyderabad.

The company which is now headquartered in Singapore post the acquisition has offices in London (UK), Ontario (Canada) and Hyderabad. It has association with 50 global scientific societies.

Pulsus is creating a SEZ at Rushikonda in Visakhapatnam, which will be fully captive. It will attract an investment of Rs 100 crore. This project will be launched by March/April this year. It will operate as a health informatics and pharmacovigilance IT and ITES unit. It also is planning to establish a skill development centre for life sciences in Visakhapatnam.